" "HC Wainwright Reiterates "$6.00" Price Target for Cancer Genetics, Inc. (NASDAQ:CGIX)

Barsaba Taglieri
Agosto 16, 2017

Ratings analysis reveals 80% of Cancer Genetics's analysts are positive. They set a "buy" rating on the stock. The company now has an average rating of "Buy" and an average target price of $5.56. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. Cancer Genetics, Inc.is headquartered in Rutherford, New Jersey. Zacks Investment Research lowered Cancer Genetics from a "buy" rating to a "hold" rating in a report on Tuesday, July 18th. They now have a Dollars 6 price target on the stock. Dawson James initiated coverage on shares of Cancer Genetics in a report on Tuesday, June 27th. The rating was initiated by Rodman & Renshaw with "Buy" on Monday, September 26. Renaissance Technologies LLC now owns 310,400 shares of the medical research company's stock valued at $419,000 after buying an additional 133,700 shares during the period. Finally, HC Wainwright set a $6.00 target price on shares of Cancer Genetics and gave the company a "buy" rating in a report on Tuesday.

Shares of Cancer Genetics, Inc. closed the previous trading session at 3.90 up +0.25 6.85% with 298,009 shares trading hands. Following the acquisition, the director now directly owns 2,542,519 shares of the company's stock, valued at approximately $9,534,446.25. The company was maintained on Friday, January 13 by RBC Capital Markets.

Among 6 analysts covering Cancer Genetics (NASDAQ:CGIX), 5 have Buy rating, 0 Sell and 1 Hold. The stock has a 50 day moving average of $3.82 and a 200 day moving average of $3.45. (NASDAQ:CGIX) to report earnings on Aug, 14 for the fiscal quarter ending Jun 2017. The company had revenue of $7 million during the quarter, compared to the consensus estimate of $7.62 million. It turned negative, as 5 investors sold Cancer Genetics Inc shares while 8 reduced holdings. The firm's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter previous year, the firm posted ($0.28) earnings per share. Blackrock Fund has invested 0% in Cancer Genetics Inc (NASDAQ:CGIX).

TRADEMARK VIOLATION NOTICE: This report was originally published by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this report on another publication, it was stolen and reposted in violation of U.S. and worldwide copyright & trademark laws.

Several analysts have released their opinion on Cancer Genetics, Inc.

In other Cancer Genetics news, Director John Pappajohn acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, June 12th. The shares were acquired at an average price of $3.75 per share, for a total transaction of $375,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last quarter, insiders acquired 103,437 shares of company stock worth $388,076. Corporate insiders own 21.30% of the company's stock. KCG Holdings Inc. purchased a new position in Cancer Genetics during the first quarter worth approximately $102,000. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics, Inc. with MarketBeat.com's FREE daily email newsletter. Northern Trust Corp boosted its stake in shares of Cancer Genetics by 61.0% in the second quarter. Finally, Thompson Davis & CO. Inc. increased its position in shares of Cancer Genetics by 5,465.0% in the second quarter. Inc. now owns 111,300 shares of the medical research company's stock worth $440,000 after buying an additional 109,300 shares during the last quarter. Institutional investors and hedge funds own 12.77% of the company's stock.

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Firm offers diagnostic services and products that enable precision medicine in the field of oncology through molecular markers and diagnostics.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE